LONG TERM DRUG SURVIVAL FOR BIOSIMILAR SB4 ETANERCEPT IN RHEUMATOID ARTHRITIS, PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS PATIENTS WITH A NON-MEDICAL SWITCH FROM ETANERCEPT REFERENCE DRUG

被引：0

作者：

Haugeberg, Glenn ^{[1
]}

Fevang, Bjorg Tilde Svanes ^{[2
]}

Bakland, Gunnstein ^{[3
]}

Rodevand, Erik ^{[4
]}

Diamantopoulos, Andreas ^{[5
]}

机构：

[1] Sorlandet Hosp Kristiansand, Rheumatol, Kristiansand, Norway

[2] Haukeland Hosp, Rheumatol, Bergen, Norway

[3] Univ Hosp North Norway HF, Rheumatol, Tromso, Norway

[4] St Olavs Hosp HF, Rheumatol, Trondheim, Norway

[5] Martina Hansens Hosp, Rheumatol, Baerum, Norway

来源：

ANNALS OF THE RHEUMATIC DISEASES | 2019年 / 78卷

关键词：

D O I：

10.1136/annrheumdis-2019-eular.7387

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

FRI0094

引用

页码：710 / 711

页数：2

共 50 条

[31] DETERMINATION OF ANTI-DRUG ANTIBODIES IN LONG-TERM TREATMENT OF RHEUMATOID ARTHRITIS PATIENTS WITH ETANERCEPT
Drynda, S.
Beuermann, R.
Kekow, J.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 : 1033 - 1034
[32] Drug-survival, effectiveness and safety of infliximab, adalimumab and etanercept in rheumatoid arthritis patients
Flendrie, M.
Creemers, M. C. W.
Welsing, P. M. J.
Van den Hoogen, F. H. J.
Van Riel, P. L. C. M.
ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 : 191 - 191
[33] Drug survival on TNF inhibitors in patients with rheumatoid arthritis comparison of adalimumab, etanercept and infliximab
Neovius, M.
Arkema, E. V.
Olsson, H.
Eriksson, J. K.
Kristensen, L. E.
Simard, J. F.
Askling, J.
ANNALS OF THE RHEUMATIC DISEASES, 2015, 74 (02) : 354 - 360
[34] 'BENEFIT' Pan-European Observational Study to Evaluate the Real-world Effectiveness of SB4 Transition from Originator Etanercept (ETN) in Patients with Rheumatoid Arthritis or Axial Spondyloarthritis: A Switch Success Story
Selmi, Carlo
Kruger, Klaus
Cantagrel, Alain
Hernandez, Abad
Freudensprung, Ulrich
Rezk, Mourad Farouk
Addison, Janet
ARTHRITIS & RHEUMATOLOGY, 2019, 71
[35] 52-week results of the phase 3 randomized study comparing SB4 with reference etanercept in patients with active rheumatoid arthritis
Emery, Paul
Vencovsky, Jiri
Sylwestrzak, Anna
Leszczynski, Piotr
Porawska, Wieslawa
Baranauskaite, Asta
Tseluyko, Vira
Zhdan, Vyacheslav M.
Stasiuk, Barbara
Milasiene, Roma
Barrera Rodriguez, Aaron Alejandro
Cheong, Soo Yeon
Ghil, Jeehoon
RHEUMATOLOGY, 2017, 56 (12) : 2093 - 2101
[36] SURVIVAL ANALYSIS OF TIME TO FIRST ADVERSE DRUG REACTION AND DRUG SURVIVAL IN RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ADALIMUMAB AND ETANERCEPT
Nguyen, M.
Velthuis, K.
Scholl, J.
Jansen, J.
Kosse, L.
Ten Klooster, P.
Jessurun, N.
Vonkeman, H.
ANNALS OF THE RHEUMATIC DISEASES, 2021, 80 : 1122 - 1122
[37] Evaluation of Radiographic Progression By Disease Activity States in Patients with Rheumatoid Arthritis Treated with SB4 or Reference Etanercept: Results from a Phase III Study
Emery, Paul
Vencovsky, Jiri
Ghil, Jeehoon
Cheong, Soo Yeon
Hong, Evelyn
ARTHRITIS & RHEUMATOLOGY, 2017, 69
[38] A Retrospective Study to Evaluate the Efficacy, Safety, and Drug Survival of Etanercept in Elderly Patients with Rheumatoid Arthritis
Shah, Alpesh
Deamude, Melissa
Mech, Cynthia
McMurray, Judi
Bensen, Robert
Bensen, William
JOURNAL OF RHEUMATOLOGY, 2013, 40 (06) : 959 - 959
[39] Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis
Piaserico, Stefano
Conti, Andrea
Messina, Francesco
Meneguzzo, Alberto
Odorici, Giulia
Bellinato, Francesco
Gisondi, Paolo
BIODRUGS, 2021, 35 (04) : 469 - 471
[40] Cross-Switch from Etanercept Originator to Biosimilar SB4 and to GP2015 in Patients with Chronic Plaque Psoriasis
Stefano Piaserico
Andrea Conti
Francesco Messina
Alberto Meneguzzo
Giulia Odorici
Francesco Bellinato
Paolo Gisondi
BioDrugs, 2021, 35 : 469 - 471

← 1 2 3 4 5 →